Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Clinical and Vaccine Immunology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY

Use of Commercial Enzyme Immunoassays To Detect Antibodies to the Herpes Simplex Virus Type 2 Glycoprotein G in a Low-Risk Population in Hanoi, Vietnam

Thoai D. Ngo, Oliver Laeyendecker, Hanh La, Wayne Hogrefe, Rhoda Ashley Morrow, Thomas C. Quinn
Thoai D. Ngo
1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Laeyendecker
1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
2Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanh La
3Department of Epidemiology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wayne Hogrefe
4Focus Technologies, Cypress, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rhoda Ashley Morrow
5Department of Laboratory of Medicine, University of Washington, Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas C. Quinn
1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
2Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tquinn@jhmi.edu
DOI: 10.1128/CVI.00437-06
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Sera from 1,238 Vietnamese women in Hanoi were tested for herpes simplex virus type 2 (HSV-2). HSV-2 prevalence was 2.0%. The Kalon and Biokit assays showed significantly higher concordance to Western blotting data than did the Focus assay (P < 0.01). Screening by Focus and then retesting with Kalon/Biokit of positive samples can reduce falsely positive results significantly (P < 0.01).

Herpes simplex virus type 2 (HSV-2) infections are increasing worldwide (6, 7), and this virus is the main cause of genital ulcer disease (1, 5). HSV-2 prevalence is often higher in developing countries than in developed countries, with higher rates in women than men (11). Additionally, HSV-2 infection appears to be a risk factor for human immunodeficiency virus acquisition and transmission (7, 13). Few epidemiologic data on HSV-2 infections are available for developing countries (5). There are increasing concerns about the performance and accuracy of various commercially available serological assays for the detection of HSV-2 antibodies (4, 9).

Enzyme-linked immunosorbent assays (ELISA) are used for the detection of antibodies to the HSV-2 glycoprotein G-2 (gG-2) (3). Rapid membrane assays are used as point-of-care tests specific for HSV-2 antibodies to gG-2 (10). Western blotting (WB) and gG monoclonal antibody blocking assays are used as the “gold standard” for confirmation (12). It cannot be inferred that the performance of an ELISA and rapid test for the detection of HSV-2 infection in industrialized countries is equally accurate in other regions of the world (8, 12).

From November to December 2004, 1,238 married women not infected with human immunodeficiency virus were recruited from four communes in the periurban Soc Son District of Hanoi, Vietnam. This study was approved by collaborating institutions’ review boards in Vietnam and the United States. A total of 1,238 serum samples were initially screened for HSV-2 antibodies with the HerpeSelect HSV-2 ELISA (Focus Technologies, Cypress, CA). A subset of 174 selected sera, including all Focus seropositive (n = 108), equivocal (n = 19), and seronegative samples (n = 47), was retested by WB performed by the University of Washington's Diagnostic Virology Laboratory (Seattle), by Kalon ELISA (Kalon Biological, Ltd., Surrey, United Kingdom), and with a Biokit rapid assay (Sure-Vue; Lexington, MA). Sera of 83 Focus ELISA HSV-2-positive but WB-negative samples were further investigated using a Focus inhibition assay performed by Focus Technologies (Cypress, CA).

The Focus ELISA detected an 8.7% (n = 108; median index value, 2.39) HSV-2 seroprevalence among the 1,238 subjects. Of the 1,111 negative samples by Focus ELISA, the median index value was 0.27 (interquartile range, 0.16 to 0.50), with 72.5% of the samples having index values below 0.5. HSV-2 prevalence was 2% (n = 25) and was screened by Focus and then confirmed by WB (Table 1).

The 174 selected sera that were tested further included 108 positive, 19 equivocal, and 47 negative by the Focus ELISA. The remaining 1,064 sera were not tested subsequently. Of the 174 serum samples, 108 (62.1%) were positive by Focus, 47 (27.0%) by Kalon, and 43 (24.7%) by Biokit (Table 1). The positive proportion for HSV-2 by all three assays was 16.7%. Focus showed 91 (52.3%) concordant results to WB, while 143 (83.4%) were seen by Kalon and 146 (83.9%) by Biokit. Within the HSV-2 Focus-negative group, six were positive by Biokit and five by Kalon. Among the 19 equivocal samples by Focus, 3 were also equivocal by Kalon and 3 were positive by Biokit. From the 108 HSV-2-seropositive samples by Focus, 26 had index values higher than 5.0, 25 fell in the 2.5 to 5.0 range, and 57 were low positives (1.1 to 2.5) (Table 1). Among Focus HSV-2-seropositive samples, there were 34 HSV-2-positive samples by Biokit and 39 by Kalon (Table 1).

The Focus inhibition assay showed 94% concordance to Focus ELISA results based on analysis of the 83 Focus HSV-2 ELISA-positive samples. Of the 83 samples tested in the inhibition assay, 3 were false positive by Focus ELISA (<60% inhibition), 6 were equivocal, 14 were negative, and 60 were true positive (≥60% inhibition). Kalon and Biokit results were 30.6% and 45.8% concordant with the Focus inhibition assay, respectively (Fig. 1).

The median percent inhibition was 94% for Kalon-positive samples (that were also Focus seropositive) and 91% for Biokit-positive samples (that were also Focus seropositive), with both assays showing two false positives according to the Focus inhibition assay results. The median percent inhibition between Kalon/Biokit negatives and Kalon/Biokit positives was significantly different (P < 0.01). Of the 69 samples that indicated HSV-2 inhibition reactivity, 5 samples showed inhibition values of <60%, while 64 samples showed ≥60% inhibition (Fig. 1). The performance of the inhibition assay showed high concordance to the Focus ELISA, similar to the results found in the HSV study from four African countries (8). However, it was not a helpful tool to evaluate the discrepancies between the Focus ELISA, Biokit, and Kalon assays.

False-negative results occurred with both the Kalon and Biokit, with 3 (12%) and 5 (20%) WB-positive samples, respectively. The false positives with Kalon (n = 36) and Biokit (n = 14) compared to those detected by Focus (n = 83) likely underestimated the actual false-positive number, because Kalon and Biokit tests were only performed on the 174 selected samples rather than the total population of 1,238.

Focus ELISA presented low concordance to WB results and detected a high number of false positives, probably due to its cutoff index value of 1.1. There was a significant difference in median index values (P < 0.01) between WB-positive and Focus-seropositive versus WB-negative but Focus-seronegative results (5.3 versus 2.9). When raising the index cutoff value of Focus from >1.1 to ≥1.8, there was a 42.2% (83 to 48) reduction in falsely positive samples. Kalon and Biokit rapid assays showed a low number of false positives within the 174 selected samples. Initial screening by Focus ELISA followed by retesting by Kalon showed false-positive results declined from 83 (47.7%) to 25 (14.4%). Retesting by Biokit of Focus ELISA positives showed a reduction to 23 (13.2%) false positives. Therefore, retesting with the Kalon ELISA and/or Biokit rapid assay of Focus HSV-2-positive samples subsequent to raising the Focus cutoff index value to ≥1.8 would reduce falsely positive samples significantly (P < 0.01).

The variations in performance among various serological tests to detect antibodies to HSV-2 may depend on the population and cross-reactivity to HSV-1 (9, 12). Most often, these serologic assays are assessed in patients attending sexually transmitted disease clinics in developed countries (2), while our study focused on sera from a population-based study in Vietnam. The inconsistencies of these assays raise concerns about their performance for the detection of HSV-2 infection in clinical settings, especially where prevalence is not well-defined.

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

Distribution of Focus HSV-2 inhibition results for 69 samples that were Focus ELISA positive but WB negative. An inhibition result of ≥60% was considered positive for HSV-2 antibodies. •, Biokit positive using Kalon ELISA index; □, Biokit negative using Kalon ELISA index; ▴, Biokit positive using Focus ELISA index; +, Biokit negative using Focus ELISA index. SD, standard deviation.

View this table:
  • View inline
  • View popup
TABLE 1.

Comparison of HSV-2 results determined by Focus ELISA to those from Biokit, Kalon, and Western blottinga

FOOTNOTES

    • Received 15 November 2006.
    • Returned for modification 16 April 2007.
    • Accepted 29 November 2007.
  • Copyright © 2008 American Society for Microbiology

REFERENCES

  1. 1.↵
    Ashley, R. L. 2001. Sorting out the new HSV type specific antibody tests. Sex. Transm. Infect.77:232-237.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Ashley-Morrow, R., D. Friedrich, and E. Krantz. 2003. Performance of the Focus and Kalon enzyme-linked immunosorbent assays for antibodies to herpes simplex virus type 2 glycoprotein G in culture-documented cases of genital herpes. J. Clin. Microbiol.41:5212-5214.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Ashley-Morrow, R., E. Krantz, and A. Wald. 2003. Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2. Sex. Transm. Dis.30:310-314.
    OpenUrlPubMedWeb of Science
  4. 4.↵
    Ashley-Morrow, R., J. Nollkamper, N. J. Robinson, N. Bishop, and J. Smith. 2004. Performance of Focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clin. Microbiol. Infect.10:530-536.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Cusini, M., and M. Ghislanzoni. 2001. The importance of diagnosing genital herpes. J. Antimicrob. Chemother.47(Suppl. T1):9-16.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Fleming, D. T., G. M. McQuillan, R. E. Johnson, A. J. Nahmias, S. O. Aral, F. K. Lee, and M. E. St. Louis. 1997. Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med.337:1105-1111.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    Gray, R. H., M. J. Wawer, R. Brookmeyer, N. K. Sewankambo, D. Serwadda, F. Wabwire-Mangen, T. Lutalo, X. Li, T. vanCott, and T. C. Quinn. 2001. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1 discordant couples in Rakai, Uganda. Lancet357:1149-1153.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    Hogrefe, W., X. Su, J. Song, R. Ashley, and L. Kong. 2002. Detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in African sera using recombinant gG2 Western blotting and gG2 inhibition. J. Clin. Microbiol.40:3635-3640.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Laeyendecker, O., C. Henson, R. H. Gray, R. H. N. Nguyen, B. J. Horne, M. J. Waver, D. Serwadda, N. Kiwanuka, R. Ashley-Morrow, W. Hogrefe, and T. C. Quinn. 2004. Performance of commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simples virus type 2-specific antibodies in Ugandans. J. Clin. Microbiol.42:1794-1796.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    Morrow, R. A., D. Friedrich, A. Meier, and L. Corey. 2005. Use of biokit HSV-2 rapid assay to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA. BMC Infect. Dis.5:84.
    OpenUrlCrossRefPubMed
  11. 11.↵
    Smith, J. S., and N. J. Robinson. 2002. Age-specific prevalence of infection with herpes simplex virus type 2 and 1: a global review. J. Infect. Dis.186(Suppl. 1):S3-S28.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    van Dyck, E., A. Buvé, H. A. Weiss, J. R. Glynn, D. W. G. Brown, B. De Deken, J. Parry, and B. J. Hayges. 2004. Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations. J. Clin. Microbiol.42:2961-2965.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    Wald, A., and K. Link. 2002. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J. Infect. Dis.185:45-52.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Use of Commercial Enzyme Immunoassays To Detect Antibodies to the Herpes Simplex Virus Type 2 Glycoprotein G in a Low-Risk Population in Hanoi, Vietnam
Thoai D. Ngo, Oliver Laeyendecker, Hanh La, Wayne Hogrefe, Rhoda Ashley Morrow, Thomas C. Quinn
Clinical and Vaccine Immunology Feb 2008, 15 (2) 382-384; DOI: 10.1128/CVI.00437-06

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Email

Thank you for sharing this Clinical and Vaccine Immunology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Use of Commercial Enzyme Immunoassays To Detect Antibodies to the Herpes Simplex Virus Type 2 Glycoprotein G in a Low-Risk Population in Hanoi, Vietnam
(Your Name) has forwarded a page to you from Clinical and Vaccine Immunology
(Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Use of Commercial Enzyme Immunoassays To Detect Antibodies to the Herpes Simplex Virus Type 2 Glycoprotein G in a Low-Risk Population in Hanoi, Vietnam
Thoai D. Ngo, Oliver Laeyendecker, Hanh La, Wayne Hogrefe, Rhoda Ashley Morrow, Thomas C. Quinn
Clinical and Vaccine Immunology Feb 2008, 15 (2) 382-384; DOI: 10.1128/CVI.00437-06
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Antibodies, Viral
Herpes Simplex
Immunoenzyme Techniques
Viral Envelope Proteins

Related Articles

Cited By...

About

  • About CVI
  • For Librarians
  • For Advertisers
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • Submit a Manuscript to mSphere

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 1556-6811; Online ISSN: 1556-679X